Higher doses of deutetrabenazine appear to be safe and well tolerated in patients with Huntington disease who may require them to adequately control chorea.
Treatment with deutetrabenazine was found to be beneficial for both younger (<55 years) and older (≥55 years) patients with tardive dyskinesia, according to findings from a recently published post hoc analysis.
Zeposia is available for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Lemborexant is now available for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adult patients.
The FDA has approved solifenacin succinate LS oral suspension for the treatment of neurogenic detrusor overactivity in pediatric patients 2 years of age and older.
This sublingual film formulation of apomorphine was designed for use as a fast-acting, on-demand treatment for all types of motor off episodes.
The FDA has approved Elyxyb (Dr. Reddy’s Laboratories), an oral solution formulation of celecoxib, for the acute treatment of migraine with or without aura in adults.
The Food and Drug Administration has approved Ongentys® as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson disease experiencing “off” episodes.
The FDA has issued new guidance regarding the use of computerized behavioral therapy and other digital health therapeutic devices for psychiatric disorders during the coronavirus disease 2019 (COVID-19) pandemic.